When Gleevec Is Not Enough: Researcher Demonstrates Value Of 'Helper' Compound In Treating Some Leukemias

Date:

November 10, 2006

Source:

Jackson Laboratory

Summary:

Researchers at the Jackson Laboratory, in collaboration with scientists at Bristol-Myers Squibb Oncology, discovered is that imatinib does not inactivate all BCR-ABL signaling pathways in the cascade. Proteins called SRC kinases are still activated by BCR-ABL in imatinib-treated mouse leukemic cells. Treatment with dasatinib, which inhibits the SRC proteins as well as BCR-ABL, was not only more effective for CML, but also led to complete B-ALL remission.

Share:

Total shares:

FULL STORY

The abberant Philadelphia chromosome is not a problem local to Philadelphia, but that's where researchers discovered the genetic mutation that's the root cause of some leukemias, including chronic myeloid leukemia (CML) and B-cell acute lymphoblastic leukemia (B-ALL). Led by Shaoguang Li, M.D., Ph.D., researchers at The Jackson Laboratory, in collaboration with scientists at Bristol-Myers Squibb Oncology, are discovering startling new information about the mechanisms of Philadelphia-positive (Ph+) leukemias that will affect how they are treated clinically.

The Philadelphia Chromosome is actually a faulty mixture of two chromosomes, 9 and 22, which typically work perfectly well independent of each other. But in rare circumstances they physically exchange genetic material in a specific way, and the combined Philadelphia chromosome merges two harmless genes into something destructive. The resulting protein, called BCR-ABL, unleashes a cascade of events that ultimately leads to unregulated cell proliferation in blood cells, leading to Ph+ leukemia.

Bone marrow transplants can cure these leukemia patients, but the procedure could be risky, and sufficiently compatible donors often cannot be found. Therefore the drug imatinib mesylate (sold by the pharmaceutical company Novartis as Gleevec), which disables the destructive function of the BCR-ABL protein, represented a huge step forward in treatment, especially for CML in chronic phase. Imatinib doesn't cure CML, but it inhibits the deadly cascade launched by BCR-ABL, and most patients can use it to better manage the disease with minimal side effects.

While imatinib helps many human patients, Li is using mice with the equivalent of the Ph+ leukemias to investigate why some do not respond to it. Also, imatinib has little positive effect for Ph+ leukemia patients that have progressed to blast crisis, the phase during which the cancer cells undergo additional changes that lead to their out-of-control reproduction. Progression to blast crisis currently necessitates a bone marrow transplant for survival.

"Sometimes the BCR-ABL protein itself has a mutation, which makes it less susceptible to imatinib," said Li. "But in some patients who do not respond to imatinib, there's no imatinib-resistant mutations detected and the disease still progresses. No one understood how that happens when the known disease cascade is inhibited."

In research published in online in the Proceedings of the National Academy of Sciences, Li's team discovered is that imatinib does not inactivate all BCR-ABL signaling pathways in the cascade. Part of the cascade, proteins called SRC kinases, are still activated by BCR-ABL in imatinib-treated mouse leukemic cells. When Li treated the mice with a compound, dasatinib, that inhibits the SRC proteins as well as BCR-ABL, he found that not only was it more effective for CML, but it also led to complete B-ALL remission.

While these results are encouraging, a small population of leukemic cells (fewer than 1 percent) persisted through treatment with imatinib or dasatinib and led to a recurrence of the leukemia. These cells, leukemic stem cells, present an additional challenge.

"These results show that clinicians need to address SRC kinase activity as well as BCR-ABL to get the best outcomes with Ph+ leukemia," said Li, "but it's not a real cure. The keys to a cure for Ph+ leukemia are the leukemic stem cells, and we've now isolated them in the mouse for the first time. We will be working hard to figure out how to target and eradicate them."

Jackson Laboratory. (2006, November 10). When Gleevec Is Not Enough: Researcher Demonstrates Value Of 'Helper' Compound In Treating Some Leukemias. ScienceDaily. Retrieved August 2, 2015 from www.sciencedaily.com/releases/2006/11/061108111443.htm

July 31, 2015  School is just around the corner, which means backpacks and packed lunches await your children. One expert offers tips for parents to promote healthy dental habits while away from ... read more

July 29, 2015  By blocking the expression of a certain gene in patients, researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their ... read more

July 29, 2015  Viewing aquarium displays led to noticeable reductions in blood pressure and heart rate, a research team found in the first study of its kind. They also noted that higher numbers of fish helped to ... read more

Mar. 10, 2014  Chronic myeloid leukaemia (CML) is associated with a specific genetic mutation that results from DNA on different chromosomes breaking off and swapping places. This disrupts genes at the breakpoint ... read more

Dec. 21, 2012  The U.S. Food and Drug Administration (FDA) this month expanded the options for patients with chronic myeloid leukemia and one form of acute lymphoblastic leukemia that carries the Philadelphia ... read more

Oct. 24, 2012  Researchers have dissected a case of synergy in drug-resistant chronic myeloid leukemia to understand the mechanism by which two drugs, danusertib and bosutinib, work together to overcome resistance ... read more

Dec. 13, 2010  The drug imatinib transformed chronic myeloid leukemia (CML) from a fatal disease to a chronic condition. However, imatinib must be taken lifelong, because it fails to kill a residual number of CML ... read more